Rentabilidad de la biopsia prostática y determinación de valores del PSA. Incidencia de cancer... Sanid. mil. 2016; 72 (4) 265 14. Lilja H, Christensson A, Dahlen U et al. Prostate specific antigen in serum occurs predominantly in complex with α-1-antichymotrypsin. Clin. Chem., 37: 1618, 1991 15. Collins GN, Alexandrou K, Wynn-Davies A, et al. Free prostate-specific antigen in the field: a useful adjunct to standard clinical practice. BJU Int, 81:419, 1998. 16. Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J. Urol., 174: 1256, 2005. 17. Hodge KK, Mcneal JE, Terris MK, et al. “Random systematic versus di-rected ultrasound guided transrectal core biopsies of the prostate”. J. Urol., 142: 71, 1989 18. Eichler K, Hempel S, Wilby J, Myers L, Kleijnen J. Diagnostic value of sys-tematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006 May;175(5):1605-12. 19. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early De-tection V.2.2007. Page: PROSD-A, 20. European Guidelines 2010. Consensus NCCN, version 1, 2007. 21. Nash PA, Bruce JE, Indudhara R, Shinohara K. Transrectal ultrasound gui-ded prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol. 1996;155 (2):607-609. 22. Eskicorapci SY, Bayda DE, Akbal C, Sofikerim M, Ekici S et al. An extended 10-core transrectal ultrasonography-guided prostate biopsy protocol impro-ves the detection of prostate cancer. Eur Urol. 2004;45(4):444- 448. 23. Beurton D, Barthe´le´my Y, Fontaine E. Twelve systematic prostate biopsies are superior to sextant biopsies for diagnosing carcinoma: a prospective ran-domized study. Br J Urol. 1997;80:239-242 24. Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol. 2000;163(1):168-171 25. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A pros-pective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol. 2000;164(2):388-392. 26. Rodríguez R, Mayayo T, Alonso M, Burgos FJ, García R. Rentabilidad de la biopsia de prostate ampliada con 10 muestras prostáticas. Estudio prospecti-vo sobre 222 pacientes. Arch Esp Urol. 2006;59(1):15-24. 27. Masters JG, Keegan PE, Hidreth AJ, et al. Free/total PSA serum prostate-specific antigen ratio: how helpful is it in detecting prostate cancer. B.J.U. International, 81: 419, 1998. 28. Veltri RW, Miller MC. Free/total PSA ratio improves differentiation of be-nign and malignant disease of the prostate: critical analysis of two different test populations. Urology, 53: 736, 1999. 29. Bangma CH, Rietbergen JBW, Kranse R, et al.The free to total prostate-specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.J. Urol., 57: 2191, 1997. 30. Stephan C, Lein M, Loening SA et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prosta-te carcinoma and benign prostate hyperplasia. Cancer 1997 Jan;79(1):104-9. 31. Catalona WJ, Partin AW, Slawin KM, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clini-cal trial. JAMA 1998 May20;279(19):1542-7. 32. Guias Europeas 2010, Consenso del NCCN, versión 1. 33. Griffith BC, Morey AF, Ali-Khan MM, Foley JP, Rozanski TA. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. J Urol. 2002; 168(3):1021-1023. 34. Bonillo MA, Bosquet M, Arlandis S, Trassierra M, Ramírez M, Jiménez JF. Profilaxis antibiótica en la biopsia de prostata. LXX Congreso Nacional de Urología. Jun 2005 35. Sieber PR, Rommel FM, Agusta VE. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol. 1997;157(6):2199-2200. 36. Aus G, Ahlgren G, Bergdahl S. Infection after transrectal core biopsies of the prostate: risk factors and antibiotic prophylaxis. Br J Urol. 1996;77(6):851- 855. 37. Norberg M, Holmberg L, Haggman M. Determinants of complications after multiple transrectal core biopsies of the prostate. Eur Radiol. 1996;6(4):457-45
REVISTA DE SANIDAD FAS OCT DIC 2016
To see the actual publication please follow the link above